HK Stock Market Move | KINTOR PHARMA-B(09939) rises more than 3% intra-day, GT20029 gel reaches primary endpoint in Phase II clinical trial for acne treatment.

KINTOR PHARMA-B (09939) rose more than 3% during trading hours, closing at a 2.86% increase, at 2.16 Hong Kong dollars, with a turnover of 8.0645 million Hong Kong dollars. On the news front, on August 12th, KINTOR PHARMA-B announced that the Phase II clinical trial of GT20029, a novel protein degrader targeting the androgen receptor (AR) for acne treatment, had achieved its primary endpoint. The data showed statistically significant and clinically meaningful results, demonstrating excellent efficacy, safety, and pharmacokinetic characteristics. The recommended dose for the Phase III clinical trial was determined to be 0.5%. Detailed topline results are expected to be disclosed in academic journals or conferences in the future. The Phase II clinical trial was a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and pharmacokinetic characteristics of GT20029 in treating acne, with doses of 0.5% QD and 1.0% QD. The trial was conducted at 10 centers nationwide, with Professor Xiang LeiHong from Fudan University's Huashan Hospital serving as the principal investigator.